ViRexx Medical Corp. (TSX:VIR) (AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B and C and embolotherapy treatments for tumors, announced today that the Company was featured as the lead story in the April 2006 issue of Biotech Monthly, a subscription-based publication primarily focused on development-stage biotechnology companies.
